Lipo-PGE1, a new lipid-encapsulated preparation of prostaglandin E1: placebo-and prostaglandin E1-controlled multicenter trials in patients with diabetic neuropathy and leg ulcers.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Prostaglandins

• Publication date

  1993-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0090-6980(93)90081-HPMID 8278621
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Iloprost, a stable prostacyclin derivative, in stage 4 arterial occlusive disease. A placebo-controlled multicenter study].

  2008cited by this paper
• Prostanoids in therapy of peripheral arterial occlusive disease.

  1991cited by this paper
• Treatment of Lower Limb Ischaemia Due to Atherosclerosis in Diabetic and Nondiabetic Patients with Iloprost, a Stable Analogue of Prostacyclin

  1991cited by this paper
• Amelioration of Nerve Na+-K+-ATPase Activity Independently of myo-Inositol Level by PGE1 Analogue OP-1206 · α-CD in Streptozocin-Induced Diabetic Rats

  1991cited by this paper
• Lipo-prostaglandin preparations.

  1991cited by this paper
• Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO Study.

  1990cited by this paper
• Distribution of lipid microspheres incorporating prostaglandin E1 to vascular lesions.

  1990cited by this paper
• A preliminary double-blind cross-over trial of lipo-PGI2, a prostacyclin derivative incorporated in lipid microspheres, in cerebral infarction.

  1990cited by this paper
• Immediate improvement of diabetic mononeuropathy after intravenous administration of prostaglandin E1.

  1990cited by this paper
• Clinical trials of PGE1, PGI2 and mimetics in patients with peripheral vascular disease.

  1989cited by this paper
• Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.

  1989cited by this paper
• Effect of Prostaglandin E1 Analogue TFC 612 on Diabetic Neuropathy in Streptozocin-Induced Diabetic Rats Comparison With Aldose Reductase Inhibitor ONO 2235

  1989cited by this paper
• Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axo-glial dysjunction in human diabetic neuropathy.

  1988cited by this paper
• A multicenter double blind controlled study of lipo-PGE1, PGE1 incorporated in lipid microspheres, in peripheral vascular disease secondary to connective tissue disorders.

  1987cited by this paper
• Marked enhancement in antithrombotic activity of isocarbacyclin following its incorporation into lipid microspheres.

  1987cited by this paper
• Experimental chronic hypoxic neuropathy: relevance to diabetic neuropathy.

  1986cited by this paper
• Pathogenesis of diabetic neuropathy

  1986cited by this paper
• Capillary number and percentage closed in human diabetic sural nerve.

  1985cited by this paper
• Prostaglandin E1 is more effective, when incorporated in lipid microspheres, for treatment of peripheral vascular diseases in man

  1983cited by this paper
• Effects of prostaglandin E1 on microvascular haemodynamics in progressive systemic sclerosis.

  1982cited by this paper
• Tissue distribution and anti-inflammatory activity of corticosteroids incorporated in lipid emulsion.

  1982cited by this paper
• A multi-clinical double blind study with PGE, (alpha-cyclodextrin clathrate) in patients with ischemic ulcer of the extremities.

  1978cited by this paper
• Intravenous prostaglandin E1 in severe peripheral vascular disease.

  1976cited by this paper

• Wound, pressure ulcer, and burn guidelines – 3: Guidelines for the diagnosis and treatment of diabetic ulcers and gangrene, second edition

  2025cites this paper
• The crosstalk among TLR2, TLR4 and pathogenic pathways; a treasure trove for treatment of diabetic neuropathy

  2022cites this paper
• Intravenous lipo-prostaglandin E1 administration for patients with acute central retinal artery occlusion

  2022cites this paper
• Prostaglandin E1 protects cardiomyocytes against hypoxia-reperfusion induced injury via the miR-21-5p/FASLG axis

  2019cites this paper
• Sphingosine-1-Phosphate Facilitates Skin Wound Healing by Increasing Angiogenesis and Inflammatory Cell Recruitment with Less Scar Formation

  2019cites this paper
• Prostaglandin E1 plus methylcobalamin combination therapy versus prostaglandin E1 monotherapy for patients with diabetic peripheral neuropathy

  2018cites this paper
• Prostaglandin E1 for diabetic neuropathy

  2017cites this paper
• Diabetic Retinopathy and Ocular Complications

  2016cites this paper
• The Therapeutic Effect of Pancreatic Kininogenase on Treatment of Diabetic Peripheral Neuropathy in Patients with Type 2 Diabetes

  2016cites this paper
• Diabetic Peripheral Neuropathy and Sexual Dysfunction

  2016cites this paper
• The wound/burn guidelines – 3: Guidelines for the diagnosis and treatment for diabetic ulcer/gangrene

  2016cites this paper
• Therapeutic effect of combined steroid-lipoprostaglandin E1 for sudden hearing loss: a propensity score-matched analysis.

  2015cites this paper
• Effects of liposomal prostaglandin E1 on periprocedural myocardial injury in patients with unstable angina undergoing an elective percutaneous coronary intervention

  2015cites this paper
• Therapeutic Effect of Zinc and Lipoprostaglandin E1 for Idiopathic Sudden Hearing Loss

  2015cites this paper
• Quantification of the effect of Lipo-PGE1 on angiogenesis.

  2015cites this paper
• Effects of lipo-prostaglandin E1 on wound bed microcirculation.

  2015cites this paper
• Liposomes contenant de la prostaglandine e1 (pge1), formulations les contenant et utilisation associée

  2011cites this paper
• An agonist sensitive, quick and simple cell-based signaling assay for determination of ligands mimicking prostaglandin E2 or E1 activity through subtype EP1 receptor: Suitable for high throughput screening

  2011cites this paper
• Prostaglandin E1 encapsulated into lipid nanoparticles improves its anti-inflammatory effect with low side-effect.

  2010cites this paper
• Vasodilator response correlates with outcome in chronic critical limb ischemia.

  2010cites this paper
• Lipo prostaglandin E1

  2009cites this paper
• Malattie dei nervi periferici

  2009cites this paper
• Long beneficial effects after lipo-prostaglandin E1 administration on the ischemic gastric tube in pigs.

  2008cites this paper
• Diabetic Neuropathies: Classification, Clinical Features, and Pathophysiological Basis

  2005cites this paper
• Beneficial effects of intravenous administration of lipo-prostaglandin E1 on the ischemic gastric tube in pigs.

  2005cites this paper
• 培養皮膚線維芽細胞によるVEGF産生に対するLipo-PG-E1(アルプロスタジル)の作用―薬剤学的血管新生療法の可能性―

  2004cites this paper
• New treatments for diabetic neuropathy: Pathogenetically oriented treatment

  2003cites this paper
• Clinical trials for drugs against diabetic neuropathy: can we combine scientific needs with clinical practicalities?

  2002cites this paper
• Diabetic neuropathy: pathogenetic background, current and future therapies

  2001cites this paper
• The therapeutic effect of lipo PGE1 on diabetic neuropathy-changes in endothelin and various angiopathic factors.

  2001cites this paper
• Specific augmentation of plantar skin blood flow by lipo-PGE1 assessed in tetrodotoxin- and N(G)-nitro-L-arginine-treated rats.

  2000cites this paper
• The Effect Of Prostaglandin E1 On Human Bone Metabolism: Evaluation By Biochemical Markers For Bone Turnover.

  2000cites this paper
• Diabetic neuropathy – a continuing enigma

  2000influential citation
• Effective Health Care Complications of diabetes : Screening for retinopathy

  1999cites this paper
• Therapy with growth factors.

  1999cites this paper
• Prostaglandin E1 prevents apoptotic cell death in superficial dorsal horn of rat spinal cord.

  1997cites this paper
• Treatment of infantile primary pulmonary hypertension by intravenous infusion of lipo-prostaglandin I2 analog.

  1997cites this paper
• Association and release of prostaglandin E1 from liposomes.

  1997cites this paper
• What is new in clinical research in wound healing.

  1997cites this paper
• Interindividual variation in the enzymatic 15-keto-reduction of 13,14-dihydro-15-keto-prostaglandin E1 in human liver and in human erythrocytes

  1997cites this paper
• Properties of prostaglandin E1.

  1996cites this paper
• Stability of lipid emulsions for drug delivery

  1996cites this paper
• Lipid microspheres as drug carriers: a pharmaceutical point of view

  1996cites this paper
• Progress in the prostaglandin E1-therapy of the intermittent claudication by means of bolus injections of LIPO-prostaglandin E1 (LIPO-PGE1)

  1996cites this paper
• Effect of beraprost sodium on response to tests of autonomic control of heart rate in patients with diabetes mellitus.

  1996cites this paper
• Randomized control trial of lipo‐prostaglandin E1 in patients with acute liver injury induced by Lipiodol‐targeted chemotherapy

  1995cites this paper
• Impairment, disability, or handicap in peripheral neuropathy: analysis of the use of outcome measures in clinical trials in patients with peripheral neuropathies.

  1995cites this paper
• Lipid microspheres for drug delivery from the pharmaceutical viewpoint.

  1994cites this paper